全文获取类型
收费全文 | 1644篇 |
免费 | 89篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 97篇 |
妇产科学 | 20篇 |
基础医学 | 165篇 |
口腔科学 | 30篇 |
临床医学 | 235篇 |
内科学 | 479篇 |
皮肤病学 | 14篇 |
神经病学 | 91篇 |
特种医学 | 299篇 |
外国民族医学 | 1篇 |
外科学 | 82篇 |
综合类 | 22篇 |
预防医学 | 44篇 |
眼科学 | 10篇 |
药学 | 108篇 |
中国医学 | 5篇 |
肿瘤学 | 37篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 5篇 |
2021年 | 13篇 |
2020年 | 6篇 |
2019年 | 9篇 |
2018年 | 26篇 |
2017年 | 11篇 |
2016年 | 25篇 |
2015年 | 29篇 |
2014年 | 32篇 |
2013年 | 38篇 |
2012年 | 51篇 |
2011年 | 55篇 |
2010年 | 63篇 |
2009年 | 75篇 |
2008年 | 58篇 |
2007年 | 52篇 |
2006年 | 53篇 |
2005年 | 56篇 |
2004年 | 43篇 |
2003年 | 48篇 |
2002年 | 42篇 |
2001年 | 44篇 |
2000年 | 44篇 |
1999年 | 44篇 |
1998年 | 67篇 |
1997年 | 67篇 |
1996年 | 78篇 |
1995年 | 61篇 |
1994年 | 50篇 |
1993年 | 60篇 |
1992年 | 28篇 |
1991年 | 27篇 |
1990年 | 30篇 |
1989年 | 46篇 |
1988年 | 35篇 |
1987年 | 34篇 |
1986年 | 37篇 |
1985年 | 29篇 |
1984年 | 25篇 |
1983年 | 18篇 |
1982年 | 29篇 |
1981年 | 15篇 |
1980年 | 12篇 |
1979年 | 8篇 |
1978年 | 9篇 |
1977年 | 16篇 |
1976年 | 12篇 |
1975年 | 14篇 |
排序方式: 共有1743条查询结果,搜索用时 46 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Common missense mutation G1528C in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromosomal localization of the mitochondrial trifunctional protein alpha subunit gene. 总被引:3,自引:2,他引:1
下载免费PDF全文
![点击此处可从《The Journal of clinical investigation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
L IJlst J P Ruiter J M Hoovers M E Jakobs R J Wanders 《The Journal of clinical investigation》1996,98(4):1028-1033
Mitochondrial trifunctional protein (MTP) is a recently identified enzyme involved in mitochondrial beta-oxidation, harboring long-chain enoyl-CoA hydratase, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and long-chain 3-ketothiolase activity. A deficiency of this protein is associated with impaired oxidation of long-chain fatty acids which can lead to sudden infant death. Furthermore, it is clear that this inborn error of fatty acid oxidation is very frequent, second to medium chain acyl-CoA dehydrogenase deficiency. In most patients only the LCHAD activity of MTP is deficient with near normal activity of the two other enzyme activities of the complex. We recently described the occurrence of a frequent G1528C mutation in the cDNA coding for the a subunit of MTP. Using S. cerevisiae for expression of wild type and mutant protein we show that the G1528C mutation is directly responsible for the loss of LCHAD activity. Furthermore, we describe a newly developed method allowing identification of the G1528C mutation in genomic DNA. The finding of an 87% allele frequency of the G1528C mutation in 34 LCHAD deficient patients makes this a valuable test for prenatal diagnosis. Finally, we show that the gene encoding the alpha subunit of MTP is located on chromosome 2p24.1-23.3. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.